The COVID-19 pandemic has exacerbated the focus on already burgeoning challenges for employers — especially when it comes to the skyrocketing costs of specialty drugs. In the current economic climate, this puts significant strain on employers already facing tough decisions around employee health benefits. In fact, the U.S. specialty market is expected to hit $310 billion by 2023, and 75% of the nearly 7,000 medications in development are specialty drugs.
Read more: 6 ways to mitigate specialty drug costs
